Nhwa Pharmaceutical gets approval for oxycodone extended-release drug

Jiangsu Nhwa Pharmaceutical Co., Ltd. recently obtained a "Drug Registration Certificate" for Oxycodone Hydrochloride Extended-Release Tablets from the National Medical Products Administration. The certificate approves the 40mg tablet for domestic production as a Category 4 chemical drug.

This newly approved drug, developed independently by Nhwa Pharmaceutical, utilizes a physicochemical barrier technology to create an extended-release formulation designed to prevent abuse of opioid medications. It is indicated for the treatment of severe pain requiring long-term, continuous opioid therapy, especially when alternative treatments are insufficient. This development is expected to enhance treatment safety for patients.

The company believes this certificate will enrich its product pipeline in the central nervous system pain management sector, boosting its market competitiveness. Nhwa Pharmaceutical plans to promptly initiate production and sales, expecting a positive impact on its future performance. The company also reminds investors to exercise caution due to potential uncertainties during the launch phase.